(Q36184962)

12 August 2017

1 reference

title

Review article: the treatment of Helicobacter pylori infection (English)

1 reference

Helicobacter pylori infectious disease

12 August 2017

1 reference

1 reference

R. V. Heatley

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A1600047

13 October 2022

language of work or name

English

0 references

publication date

1 June 1992

1 reference

full work available at URL

12 August 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1111%2Fj.1365-2036.1992.tb00051.x

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

http://onlinelibrary.wiley.com/wol1/doi/10.1111/j.1365-2036.1992.tb00051.x/fullpdf

13 October 2022

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Alimentary Pharmacology & Therapeutics

13 October 2022

published in

1 reference

12 August 2017

6

1 reference

12 August 2017

3

1 reference

12 August 2017

291-303

1 reference

Campylobacter pyloridis-associated chronic active antral gastritis. A prospective study of its prevalence and the effects of antibacterial and antiulcer treatment

12 August 2017

4

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Prevalence of Helicobacter pylori infection and histologic gastritis in asymptomatic persons.

13 October 2022

7

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration

13 October 2022

8

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

13 October 2022

Nervous dyspepsia

9

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Use of endoscopy in patients with dyspepsia

13 October 2022

11

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Campylobacter pyloriin Peptic Ulcer Disease: III. Symptoms and Paraclinical and Epidemiologic Findings

13 October 2022

12

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Campylobacter pylori--a role in non-ulcer dyspepsia?

13 October 2022

14

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Effect of colloidal bismuth subcitrate on symptoms and gastric histology in non-ulcer dyspepsia. A double blind placebo controlled study

13 October 2022

15

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Non-ulcer dyspepsia and short term De-Nol therapy: a placebo controlled trial with particular reference to the role of Campylobacter pylori

13 October 2022

17

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Campylobacter associated gastritis in patients with non-ulcer dyspepsia: a double blind placebo controlled trial with colloidal bismuth subcitrate

13 October 2022

18

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Campylobacter pylori-associated gastritis: a double-blind placebo-controlled trial with amoxycillin

13 October 2022

21

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Nitrofurans in the treatment of gastritis associated with Campylobacter pylori. The Gastrointestinal Physiology Working Group of Cayetano Heredia and The Johns Hopkins Universities.

13 October 2022

22

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Prophylactic effect of cimetidine in duodenal ulcer disease

13 October 2022

23

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

The presence of spirochetes in human gastric mucosa

13 October 2022

26

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Double-blind short-term trial of furazolidone in peptic ulcer

13 October 2022

27

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Furazolidone in peptic ulcer

13 October 2022

28

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Helicobacter pylori and peptic ulceration: histopathological aspects

13 October 2022

29

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Campylobacter pylori and duodenal ulcers: the gastrin link

13 October 2022

30

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Lowered gastrin and gastric acidity after eradication of Campylobacter pylori in duodenal ulcer

13 October 2022

31

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Campylobacter pyloridis and acid induced gastric metaplasia in the pathogenesis of duodenitis

13 October 2022

32

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Mucosal IgA recognition of Helicobacter pylori 120 kDa protein, peptic ulceration, and gastric pathology

13 October 2022

33

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Difference in relapse rates of duodenal ulcer after healing with cimetidine or tripotassium dicitrato bismuthate

13 October 2022

34

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Cimetidine and colloidal bismuth in treatment of chronic duodenal ulcer. Comparison of initial healing and recurrence after healing

13 October 2022

35

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Comparison of Cimetidine and Tripotassium Dicitrato Bismuthate in Healing and Relapse of Duodenal Ulcers

13 October 2022

36

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Healing and recurrence of duodenal ulcer after treatment with tripotassium dicitrato bismuthate (TDB) tablets or cimetidine

13 October 2022

37

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Campylobacter pylori and recurrence of duodenal ulcers--a 12-month follow-up study

13 October 2022

38

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Relapse rates in duodenal ulcer patients formerly treated with bismuth subcitrate or maintained with cimetidine

13 October 2022

40

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Campylobacter pylori and ulcer recurrence

13 October 2022

41

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials

13 October 2022

42

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies

13 October 2022

45

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

PROSPECTIVE DOUBLE-BLIND TRIAL OF DUODENAL ULCER RELAPSE AFTER ERADICATION OF CAMPYLOBACTER PYLORI

13 October 2022

46

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Cure of duodenal ulcer after eradication of Helicobacter pylori

13 October 2022

50

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Transfer of Campylobacter pylori and Campylobacter mustelae to Helicobacter gen. nov. as Helicobacter pylori comb. nov. and Helicobacter mustelae comb. nov., Respectively

13 October 2022

52

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Susceptibility of clinical isolates of Campylobacter pyloridis to 11 antimicrobial agents

13 October 2022

54

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Campylobacter pylori gastritis: long term results of treatment with amoxycillin

13 October 2022

56

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Antacids reduce Campylobacter pylori colonization without healing the gastritis in patients with nonulcer dyspepsia and erosive prepyloric changes

13 October 2022

58

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

The efficacy of antimicrobial treatment in Campylobacter pylori-associated gastritis and duodenal ulcer.

13 October 2022

59

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Omeprazole, campylobacter pylori, and duodenal ulcer

13 October 2022

60

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Omeprazole, Helicobacter pylori, gastritis, and duodenal ulcer

13 October 2022

61

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Omeprazole and Helicobacter pylori: temporary suppression rather than true eradication

13 October 2022

62

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Short report: the effect of omeprazole on Helicobacter pylori and associated gastritis

13 October 2022

63

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Adjuvant antibiotic therapy in duodenal ulcers treated with colloidal bismuth subcitrate

13 October 2022

64

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

A potential mechanism of action of colloidal bismuth subcitrate: diffusion barrier to hydrochloric acid

13 October 2022

65

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Studies on the gastroprotective and ulcer-healing effects of colloidal bismuth subcitrate

13 October 2022

66

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

De-Nol stimulates gastric and duodenal alkaline secretion through prostaglandin dependent mechanism

13 October 2022

67

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Acid, pepsin, and mucus secretion in patients with gastric and duodenal ulcer before and after colloidal bismuth subcitrate (De-Nol).

13 October 2022

69

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

The safety profile of De-Nol

13 October 2022

70

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Helicobacter pylori infection and duodenal ulcer

13 October 2022

73

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Eradicating Helicobacter pylori and symptoms of non-ulcer dyspepsia

13 October 2022

79

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

One week eradication regimen for Helicobacter pylori

13 October 2022

81

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

Dyspepsia: a dilemma for doctors?

13 October 2022

82

1 reference

https://api.crossref.org/works/10.1111/J.1365-2036.1992.TB00051.X

13 October 2022

Identifiers

1 reference

National Center for Biotechnology Information

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/esummary.fcgi?db=pubmed&retmode=json&id=1600047

13 October 2022

1 reference